Avacta Group PLC Appointment of Chief Business Officer (2187X)
19 Dicembre 2023 - 8:00AM
UK Regulatory
TIDMAVCT
RNS Number : 2187X
Avacta Group PLC
19 December 2023
19 December 2023
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Appointment of Chief Business Officer
Appointment signals commercial emphasis for Avacta to leverage
clinical progress
Avacta Group plc (AIM: AVCT), a life sciences company developing
innovative, targeted oncology drugs and powerful diagnostics, is
pleased to announce the appointment of Dr Simon Bennett as Chief
Business Officer of the Therapeutics Division.
Simon has over 26 years' commercial experience in the biopharma
industry. He has worked with companies from large and mid-sized
pharma such as Bristol-Myers-Squibb and Menarini Group to early
stage biotechs, supporting business development and licensing
activities in addition to being involved in all aspects of business
and corporate development. Simon has been involved in over 80
commercial deals across Europe, North America, Australasia, Japan,
Russia/CIS and South America.
Dr Alastair Smith, Chief Executive Officer of Avacta Group,
commented:
"As Chief Business Officer, Simon will work closely with the
senior management team and lead commercial strategy and business
development activities at this exciting period in the Company's
development as compelling clinical data emerges from the AVA6000
phase 1 trial.
"These emerging data give us, for the first time, the
opportunity to accelerate ongoing discussions as well as to
generate new opportunities through our business development
activities aimed at delivering licensing opportunities for the
pre|CISION(TM) and Affimer(R) platforms."
Simon's career began at University of Oxford spin-out, Oxagen
Limited where he established and built a franchise in Women's
Health, initially as Programme Director and later as Director of
Business Development. He subsequently joined next generation
sequencing company Solexa where, as Business Development Director,
he was responsible for all commercial activities and external
communications leading up to the reverse takeover of Nasdaq-listed
Lynx Therapeutics to form Solexa Inc. which was later acquired by
Illumina. Since then, Simon has worked as a consultant providing
expert commercial and business development resources to a wide
range of biopharmaceutical companies. Prior to moving into
industry, Simon was a Wellcome Trust Research Fellow at the
University of Oxford and an Honorary Clinical Lecturer at Imperial
College London. He has published widely, particularly in the field
of complex disease genetics.
Dr Simon Bennett, Chief Business Officer, Avacta Therapeutics
commented:
"Avacta is at a pivotal point, having recently announced
clinical data that have already begun to generate interest from
potential commercial partners. I am delighted to be joining at such
an exciting point in the journey of the business, to help the team
optimise the commercial opportunities of their technologies and
assets."
- Ends-
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0) 1904 21 7070
Alastair Smith, Chief Executive www.avacta.com
Officer
Tony Gardiner, Chief Financial Officer
Michael Vinegrad, Group Communications
Director
Stifel Nicolaus Europe Limited (Nomad Tel: +44 (0) 207 710 7600
and Joint Broker) www.stifel.com
Nicholas Moore / Nick Adams / Samira
Essebiyea / Nick Harland / William
Palmer-Brown
Peel Hunt (Joint Broker) Tel: +44 (0) 207 418 8900
James Steel / Chris Golden / Patrick www.peelhunt.com
Birkholm
ICR Consilium (Media and IR) avacta@consilium-comms.com
Mary-Jane Elliott / Jessica Hodgson
/ Sukaina Virji
About Avacta Group plc - https://www.avacta.com
Avacta Group is a UK-based company focused on improving
healthcare outcomes through targeted cancer treatments and
diagnostics.
Avacta has two divisions: an oncology biotech division
harnessing proprietary therapeutic platforms to develop novel,
highly targeted cancer drugs, and a diagnostics division, which is
executing on an M&A led growth strategy to create a
full-spectrum diagnostics business focused on supporting healthcare
professionals and broadening access to testing. Avacta's two
proprietary platforms, Affimer(R) and pre|CISION(TM) underpin its
cancer therapeutics whilst the diagnostics division leverages the
Affimer(R) platform to drive competitive advantage in its
markets.
The pre|CISION(TM) platform modifies chemotherapy to be
activated only in the tumour tissue, reducing systemic exposure and
toxicity. This is achieved by harnessing an enzyme called FAP which
is highly upregulated in most solid tumours compared with healthy
tissues, turning chemotherapy into a "precision medicine". The lead
pre|CISION(TM) programme, AVA6000 a tumour activated form of
doxorubicin, is in Phase 1 studies and has shown dramatic
improvement in safety compared with standard doxorubicin, and early
signs of clinical activity.
Affimer(R) is a novel biologic platform which has significant
technical and commercial advantages compared with antibodies and is
used both to develop advanced immunotherapies and to improve the
performance of immunodiagnostics.
With a balanced business and capital allocation model: a
high-value oncology pipeline supported by a revenue generating,
fast-growing diagnostics business, Avacta seeks to create long-term
shareholder value alongside patient benefit.
To register for news alerts by email go to
https://avacta.com/investors/investor-news-email-alerts/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFFEEFAEDSEFE
(END) Dow Jones Newswires
December 19, 2023 02:00 ET (07:00 GMT)
Grafico Azioni Avacta (LSE:AVCT)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Avacta (LSE:AVCT)
Storico
Da Mag 2023 a Mag 2024